Background: The impact of possible tardive dyskinesia (TD) was assessed in RE KINECT, a real-world study of antipsychotic-treated outpatients. Based on clinician assessments, patients were assigned to Cohort 1 (no involuntary movements, N=450) or Cohort 2 (clinician-confirmed possible TD, N=204). Analyses were conducted to evaluate health related quality of life (HRQoL) (Cohort 2 vs. Cohort 1) and effects of possible TD on HRQoL (Cohort 2).
Methods: Assessments included EuroQoL 5-Dimension 5-Level (EQ-5D-5L); Sheehan Disability Scale (SDS); patient- and clinician-rated severity of possible TD; and patient-rated impact of possible TD. Regression models were used to analyze the following: mean differences between Cohort 2 and Cohort 1 in EQ-5D-5L utility and SDS total scores; and associations between clinician and patient ratings of possible TD (severity, impact) and HRQoL (EQ-5D-5L, SDS).
Results: A significant mean difference between Cohort 2 and Cohort 1 was found for EQ-5D-5L utility score (-0.037; P < 0.05). In Cohort 2 patients who self-reported “a lot” of TD severity (n=53) or impact (n=33), EQ-5D-5L and SDS scores were both significantly worse than in Cohort 1 (P < 0.05). Patient self-ratings (impact and severity of possible TD) were significantly associated with EQ-5D-5L utility; no significant association was found with clinician-rated severity. Results for SDS total score were similar.
Conclusions: RE-KINECT patients were consistent in evaluating the severity and impact of TD, whether based on subjective assessments or standardized patient-reported instruments (EQ-5D-5L, SDS). Incorporating patient self-assessments (focused on symptom impact) into everyday clinical practice may provide a more comprehensive approach to TD assessment and management.
This poster was presented at the 32nd annual Psych Congress, held Oct. 3-6, 2019, in San Diego, California.